For HER2 positive breast cancer patients, disease relapse might occur even after standard anti-HER2 therapy (He et al., 2011; Zhou et al., 2014; Yuan et al., 2015; Zhu et al., 2017; Zhu et al., 2018). The gene discussed is ERBB2; the disease is breast cancer.